Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.80
-1.7%		$25.41
$21.02
▼
$42.21
$2.77B0.11.95 million shs1.18 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.74
-9.4%		$7.11
$2.99
▼
$8.98
$3.04B0.924.96 million shs10.24 million shs
uniQure N.V. stock logo
QURE
uniQure
$22.80
-2.8%		$42.99
$8.73
▼
$71.50
$1.63B1.063.20 million shs3.04 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$8.00
+3.9%		$7.25
$3.43
▼
$10.82
$697.34M0.392.27 million shs2.22 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+2.75%-8.66%-33.52%-24.36%
Precigen, Inc. stock logo
PGEN
Precigen
0.00%+10.19%+20.28%+52.50%+162.77%
uniQure N.V. stock logo
QURE
uniQure
0.00%-38.63%-47.28%-43.28%-57.28%
Verastem, Inc. stock logo
VSTM
Verastem
0.00%-0.52%-6.10%+72.65%-11.49%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.80
-1.7%		$25.41
$21.02
▼
$42.21
$2.77B0.11.95 million shs1.18 million shs
Precigen, Inc. stock logo
PGEN
Precigen
$7.74
-9.4%		$7.11
$2.99
▼
$8.98
$3.04B0.924.96 million shs10.24 million shs
uniQure N.V. stock logo
QURE
uniQure
$22.80
-2.8%		$42.99
$8.73
▼
$71.50
$1.63B1.063.20 million shs3.04 million shs
Verastem, Inc. stock logo
VSTM
Verastem
$8.00
+3.9%		$7.25
$3.43
▼
$10.82
$697.34M0.392.27 million shs2.22 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+2.75%-8.66%-33.52%-24.36%
Precigen, Inc. stock logo
PGEN
Precigen
0.00%+10.19%+20.28%+52.50%+162.77%
uniQure N.V. stock logo
QURE
uniQure
0.00%-38.63%-47.28%-43.28%-57.28%
Verastem, Inc. stock logo
VSTM
Verastem
0.00%-0.52%-6.10%+72.65%-11.49%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.00114.91% Upside
Precigen, Inc. stock logo
PGEN
Precigen
2.83
Moderate Buy$13.6776.57% Upside
uniQure N.V. stock logo
QURE
uniQure
2.75
Moderate Buy$53.73135.65% Upside
Verastem, Inc. stock logo
VSTM
Verastem
2.73
Moderate Buy$13.8372.92% Upside

Current Analyst Ratings Breakdown

Latest VSTM, PGEN, NAMS, and QURE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/5/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$50.00 ➝ $42.00
10/5/2026
uniQure N.V. stock logo
QURE
uniQure
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$60.00 ➝ $28.00
10/5/2026
Verastem, Inc. stock logo
VSTM
Verastem
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
10/5/2026
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
10/2/2026
uniQure N.V. stock logo
QURE
uniQure
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$65.00 ➝ $48.00
9/30/2026
uniQure N.V. stock logo
QURE
uniQure
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$46.00 ➝ $31.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$75.00
9/29/2026
uniQure N.V. stock logo
QURE
uniQure
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/28/2026
Verastem, Inc. stock logo
VSTM
Verastem
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/25/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
9/24/2026
Precigen, Inc. stock logo
PGEN
Precigen
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M121.13N/AN/A$5.97 per share3.82
Precigen, Inc. stock logo
PGEN
Precigen
$9.68M285.06N/AN/A$0.06 per share129.00
uniQure N.V. stock logo
QURE
uniQure
$16.10M98.24N/AN/A$3.19 per share7.15
Verastem, Inc. stock logo
VSTM
Verastem
$30.91M23.44N/AN/A$0.74 per share10.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
Precigen, Inc. stock logo
PGEN
Precigen
-$250.64M-$1.04N/A10.60N/A-183.98%423.75%84.39%11/12/2026 (Estimated)
uniQure N.V. stock logo
QURE
uniQure
-$198.97M-$4.01N/AN/AN/A-1,350.73%-111.96%-29.01%11/9/2026 (Estimated)
Verastem, Inc. stock logo
VSTM
Verastem
-$209.47M-$2.66N/AN/AN/A-231.59%-467.49%-94.54%11/3/2026 (Estimated)

Latest VSTM, PGEN, NAMS, and QURE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Verastem, Inc. stock logo
VSTM
Verastem
-$0.4305-$0.35+$0.0805-$0.35$22.88 million$40.08 million
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
8/4/2026Q2 2026
Precigen, Inc. stock logo
PGEN
Precigen
-$0.0121$0.05+$0.0621$0.05$27.98 million$54.98 million
7/29/2026Q2 2026
uniQure N.V. stock logo
QURE
uniQure
-$0.8223-$1.22-$0.3977-$1.22$5.45 million$5.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Precigen, Inc. stock logo
PGEN
Precigen
N/AN/AN/AN/AN/A
uniQure N.V. stock logo
QURE
uniQure
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
Precigen, Inc. stock logo
PGEN
Precigen
2.15
4.58
3.89
uniQure N.V. stock logo
QURE
uniQure
0.15
10.01
10.01
Verastem, Inc. stock logo
VSTM
Verastem
1.48
2.25
2.22

Institutional Ownership

CompanyInstitutional Ownership
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Precigen, Inc. stock logo
PGEN
Precigen
33.51%
uniQure N.V. stock logo
QURE
uniQure
78.83%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
Precigen, Inc. stock logo
PGEN
Precigen
41.40%
uniQure N.V. stock logo
QURE
uniQure
4.65%
Verastem, Inc. stock logo
VSTM
Verastem
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
100119.54 million104.31 millionOptionable
Precigen, Inc. stock logo
PGEN
Precigen
47356.51 million208.92 millionOptionable
uniQure N.V. stock logo
QURE
uniQure
22169.37 million66.14 millionOptionable
Verastem, Inc. stock logo
VSTM
Verastem
10290.56 million88.81 millionOptionable

Recent News About These Companies

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 5 at 4:02 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261002207190/en/verastem-oncology-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4/
Verastem (NASDAQ:VSTM) Stock Keeps "Buy" Rating at BTIG Research
October 5 at 8:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086575
Verastem (NASDAQ:VSTM) Earns Buy Rating from HC Wainwright
October 5 at 8:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086567
Verastem (NASDAQ:VSTM) Earns Buy Rating from BTIG Research
October 5 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-earns-buy-rating-from-btig-research-2026-10-05/
Verastem (NASDAQ:VSTM) Given Buy Rating at HC Wainwright
October 5 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-given-buy-rating-at-hc-wainwright-2026-10-05/
Durable Efficacy Data in LGSOC Reinforce Verastem Franchise and Label Expansion Potential; Buy Rating Reiterated with Unchanged $18 Price Target
October 5 at 7:11 AM  |  tipranks.comhttps://www.tipranks.com/news/ratings/durable-efficacy-data-in-lgsoc-reinforce-verastem-franchise-and-label-expansion-potential-buy-rating-reiterated-with-unchanged-18-price-target-ratings-news?utm_source=marketbeat.com&utm_medium=referral
Verastem (NASDAQ:VSTM) CFO Daniel Calkins Sells 2,566 Shares of Stock
October 3 at 6:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31083241
Verastem (NASDAQ:VSTM) CFO Sells 2,566 Shares of Stock
October 3 at 5:52 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-vstm-insider-buying-and-selling-2026-10-03/
Verastem (NASDAQ:VSTM) CEO Dan Paterson Sells 44,121 Shares of Company Stock
October 3 at 5:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082871
Verastem (NASDAQ:VSTM) CFO Sells 2,566 Shares of Company Stock
October 2 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-verastem-nasdaq-vstm-cfo-sells-2566-shares-of-company-stock-2026-10-02/
Verastem (NASDAQ:VSTM) CEO Sells $352,968.00 in Stock
October 2 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-verastem-nasdaq-vstm-ceo-sells-35296800-in-stock-2026-10-02/
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade ...
October 2 at 12:04 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/verastem-oncology-announces-ramp-201-113000590.html
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
October 2 at 8:00 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261002351312/en/Verastem-Oncology-Announces-New-RAMP-201-Molecular-Profiling-and-External-Control-Arm-Analyses-Describing-Outcomes-for-Avutometinib-Plus-Defactinib-in-Recurrent-Low-Grade-Serous-Ovarian-Cancer-to-be-Presented-at-IGCS-2026/
Head-To-Head Analysis: ADC Therapeutics (NYSE:ADCT) vs. Verastem (NASDAQ:VSTM)
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072228
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules ...
September 29, 2026  |  marketscreener.comM
Financial Review: Sangamo Therapeutics (NASDAQ:SGMO) versus Verastem (NASDAQ:VSTM)
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063546
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
September 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260928878351/en/verastem-oncology-announces-publication-in-gynecologic-oncology-of-two-year-median-follow-up-data-from-ramp-201-study-of-avmapki%c2%ae-fakzynja%c2%ae-co-pack-avutometinib-capsules-defactinib-tablets-in-recurrent-low-grade-serous-ovarian-cancer/
Financial Comparison: Nektar Therapeutics (NASDAQ:NKTR) and Verastem (NASDAQ:VSTM)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053983
Verastem (NASDAQ:VSTM) Raised to "Hold" at Wall Street Zen
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053709
Verastem (NASDAQ:VSTM) Upgraded to Hold at Wall Street Zen
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-verastem-nasdaq-vstm-upgraded-to-hold-at-wall-street-zen-2026-09-27/
Verastem data on ovarian cancer drug combo set for IGCS 2026
September 25, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Verastem+data+on+ovarian+cancer+drug+combo+set+for+IGCS+2026/27099336.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$22.80 -0.40 (-1.72%)
Closing price 04:00 PM Eastern
Extended Trading
$22.82 +0.02 (+0.07%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Precigen stock logo

Precigen NASDAQ:PGEN

$7.74 -0.80 (-9.37%)
Closing price 04:00 PM Eastern
Extended Trading
$7.78 +0.04 (+0.52%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

uniQure stock logo

uniQure NASDAQ:QURE

$22.80 -0.66 (-2.81%)
Closing price 04:00 PM Eastern
Extended Trading
$22.59 -0.21 (-0.94%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Verastem stock logo

Verastem NASDAQ:VSTM

$8.00 +0.30 (+3.90%)
Closing price 04:00 PM Eastern
Extended Trading
$7.82 -0.18 (-2.19%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas